$13.34
-0.22-1.62%
近くで: Nov 19, 4:00 PM EST
$13.34
N/A
時間外: 4:00 PM EST

ADMA Biologics (ADMA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $0.23 | $0.20 | 15.0 % |
| Q2 | Aug 5, 2026 | $0.16 | $0.17 | -5.88 % |
| Q1 | May 6, 2026 | $0.17 | $0.20 | -15.0 % |
| Q4 | Feb 25, 2026 | $0.22 | $0.20 | 7.50 % |
Quarterly Revenue (Billions)
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $141.10M | $138.46M | 1.91 % |
| Q2 | Aug 5, 2026 | $124.40M | $126.08M | -1.34 % |
| Q1 | May 6, 2026 | $114.49M | $139.97M | -18.2 % |
| Q4 | Feb 25, 2026 | $139.16M | $139.80M | -0.46 % |
ADMA Biologics (ADMA) は、11 4, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高をの範囲と予想しています。
以前のガイダンスと比較して、ADMA Biologicsは売上高予測を以前の範囲である維持から$530M - $560Mに引き上げました。
ADMA Biologicsは、14から12 6, 2022の間に8 5, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 7 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.20 | $0.17 | $0.20 | $0.20 |
| Actual | $0.23 | $0.16 | $0.17 | $0.21 |
| Surprise | +15.0% | -5.88% | -15.0% | +7.50% |
| Revenue | ||||
| Estimate | $138.5M | $126.1M | $140.0M | $139.8M |
| Actual | $141.1M | $124.4M | $114.5M | $139.2M |
| Surprise | +1.91% | -1.34% | -18.2% | -0.46% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.23 | $0.18 | $0.18 | $0.20 |
| Revenue | ||||
| Consensus | $154.6M | $135.3M | — | — |